Biomarkers /
PPP2R2A
Overview
PPP2R2A is altered in 0.51% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, cervical squamous cell carcinoma, conventional glioblastoma multiforme, and lung adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in PPP2R2A are PPP2R2A Mutation (0.61%), PPP2R2A Loss (0.62%), PPP2R2A Amplification (0.50%), PPP2R2A N386S (0.08%), and PPP2R2A R298Q (0.07%) [3].
Clinical Trials
Significance of PPP2R2A in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.